Try our Advanced Search for more refined results

Arbutus Biopharma Corporation et al v. Moderna, Inc. et al

Track this case

Case overview

Case Number:

1:22-cv-00252

Court:

Delaware

Nature of Suit:

Patent

Judge:

Joshua D. Wolson

Firms

Companies

Sectors & Industries:

  1. August 20, 2025

    Feds Lose Bid To Seal In Vax Patent Case Against Moderna

    The U.S. government has failed to show why names and contact information of certain U.S. Department of the Army employees should be hidden in an mRNA vaccine developer's $5 billion patent suit over Moderna's COVID-19 vaccines, a federal judge has found.

  2. August 04, 2025

    Moderna Seeks To Be Cleared In $5B COVID Vax Patent Case

    Moderna has urged a Delaware federal judge to clear it in a rival mRNA vaccine developer's $5 billion patent suit over the company's COVID-19 vaccines, saying it is shielded because it made them for the federal government.

  3. May 20, 2025

    Moderna Says Order To Narrow Vax IP Case Should Stay

    Moderna has said that a federal judge should ignore a rival mRNA developer's request to rethink his decision limiting issues in a patent suit over the company's COVID-19 vaccines, saying the rival is trying to make new arguments too late.

  4. March 04, 2025

    Moderna Faces MRNA Vax Patent Suits In Canada And Beyond

    Pennsylvania drug developer Arbutus Biopharma and Genevant Sciences have taken their COVID-19 vaccine litigation against Moderna worldwide, suing the pharmaceutical company in courts in Canada, Japan and Switzerland, along with the Unified Patent Court, alleging infringement.

  5. August 20, 2024

    Vax Patent Battles Heat Up As Attention On Pandemic Wanes

    It's been over four years since clinical trials began for COVID-19 vaccines, and while the shots have helped the pandemic recede, the lucrative technology has spurred numerous patent suits, many of which are still in the early stages. Here's a look at some of the key cases in the U.S.

  6. March 10, 2023

    Judge Not Convinced By DOJ's 'Say-So' In Vax IP Row

    Deciding that it wasn't going to be immediately swayed by "the government's say-so," a Delaware federal court on Friday quickly turned down the Biden administration's efforts to subsume liability for part of a billion-dollar patent dispute over the ownership of the mRNA platform used in Moderna's COVID-19 vaccines.

  7. March 08, 2023

    Moderna Tries To Kick Ex-Judge Out Of COVID Vax IP Row

    Moderna has responded to arguments from a former top federal judge, among other legal academics and pharmaceutical trade organizations that are weighing in on a billion-dollar patent lawsuit over the ownership of the mRNA platform behind one of the COVID-19 vaccines, by asking a federal judge in Delaware to disregard those arguments entirely.

  8. March 03, 2023

    Ex-Judges Worried About Where COVID Vax IP Row Will Go

    The Biden administration's position that the government should be the target of a billion-dollar patent suit over Moderna's COVID-19 vaccine in federal claims court has been decried by that court's former top judge and other officials, who say that approach flouts patent law.

  9. February 14, 2023

    Moderna Is Wrong Target Of COVID Vax IP Claims, Feds Say

    The U.S. government urged a Delaware federal judge on Tuesday to toss claims accusing Moderna Inc. of infringing the patents of a rival mRNA developer with its COVID-19 vaccine, saying that because the vaccine was developed for the government, the claims can only target the government.

  10. November 02, 2022

    Moderna Loses Bid To Punt COVID Vax Patent Suit To Gov't

    Moderna Inc. must continue to fight claims that it infringed the patents of a rival mRNA developer with its COVID-19 vaccine, a Delaware federal judge ruled Wednesday in finding Moderna can't yet establish that the vaccine was developed specifically "for the government," thus shielding it from the litigation.